Navigation Links
Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results
Date:2/29/2008

WOODCLIFF LAKE, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported fourth quarter and full year 2007 results ended December 31, 2007.

Fourth Quarter and 2007 Results

For the fourth quarter ended December 31, 2007, Par reported total revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share. This is compared with reported revenues of $183.6 million and income from continuing operations of $5.0 million, or $0.15 per diluted share, for the same period in 2006. For the year ended December 31, 2007, Par reported total revenues of $769.7 million and income from continuing operations of $51.1 million, or $1.47 per diluted share. This is compared with reported revenues of $725.2 million and income from continuing operations of $6.7 million, or $0.19 per diluted share, for 2006.

Fourth quarter 2007 reported, or GAAP, income from continuing operations included a pre-tax gain of $3.1 million from the Company's sale of its remaining investment in Optimer Pharmaceutical, Inc. ("Optimer") common stock and $4.6 million of additional share-based compensation expense related to the Company's issued stock option tender offer. Adjusting for these items, income from continuing operations for the fourth quarter of 2007 was $6.5 million, or $0.19 per diluted share. By comparison, income from continuing operations for fourth quarter 2006 included a $3.2 million investment gain, tempered by severance costs of $5.2 million, and a $1.0 million asset impairment. Adjusting for these items, income from continuing operations for the fourth quarter of 2006 was $6.9 million, or $0.20 per diluted share.

Par's reported, or GAAP, income from cont
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008
2. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
5. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
8. Lotus Pharmaceuticals Raises $5 Million in Private Placement
9. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
10. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 T.E.N., ... relationship-marketing firm, honored finalists and winners Wednesday evening, ... Forum and Awards Gala at the Westin St. ... director of information security for the BlackLine Systems, ... the Year Award winner for the ISE® West ...
(Date:7/31/2014)... Amy Norton HealthDay ... Babies born with so-called "bubble boy" disease can often be ... -- but early treatment is critical, a new study finds. ... known, actually refers to a group of rare genetic disorders ... at high risk of severe infections. The term "bubble ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Recovery time after surgery ... known as statins, according to a new study. ... affect the body,s inflammatory response, reducing the amount of ... seemed to be particularly true among people who tend ... of the most widely prescribed medications in the world. ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ... to reach $702m by 2020, increasing slowly ... market will be driven by: the rising ... incurred by government agencies, such as Medicare, ... adoption of innovative technologies such as flow ...
(Date:7/31/2014)... July 31, 2014 -- A new study by researchers ... a peptide called caerulein can convert existing cells in ... diabetes-insulin-producing beta cells. The study, published online July 31 ... new approach to treating the estimated 3 million people ... with type 1 diabetes. , "We have found a ...
Breaking Medicine News(10 mins):Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 2Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 5Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2
... to be Delayed, CAMBRIDGE, Mass., Nov. 13 ... has received a letter from the U.S.,Food and Drug ... for Synvisc-One(TM) in the United,States. The company now expects ... be delayed in the U.S. until at least the,second ...
... to avoid may offer protection , TUESDAY, Nov. 13 (HealthDay ... meats may help improve the chances of surviving a heart ... of a preliminary study in the Nov. 12 online edition ... . , Researchers found that mice fed extra nitrite ...
... house,abandoned older pets, who spend their last days watching ... kittens. November is Adopt-a-Senior-Pet Month and is dedicated ... and the fulfillment they can bring to the,right owner. ... these animals have been,surrendered," said Brent Hinton, former Kentucky ...
... water work,well for simple cleaning, they won,t do the ... illness. Something stronger must be used. U.S. Nonwovens ... this pressing problem. Rediwipes are proven to kill,99.9 percent ... "The first cardinal rule of safe food preparation in ...
... Inc.,(Nasdaq: CLRT ), a premier technology and ... today announced,that it was ranked #19 on Deloitte,s ... was also named to Deloitte,s 2007 Technology Fast ... Fast 50 is a ranking of the 50,fastest ...
... - No Human Vaccine Currently Exists Against the ... Deaths in the US so far in 2007;,Collaboration Aims ... as Rapidly as Possible Acambis plc (Acambis) (LSE: ... has signed an exclusive global,collaboration agreement with Sanofi Pasteur, ...
Cached Medicine News:Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 2Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 3Health News:Nitrite, Nitrate-Rich Foods Boost Heart Attack Outcomes 2Health News:Old Dogs Can Learn New Tricks 2Health News:Disinfecting Rediwipes(TM) Launch Targets E. coli and Salmonella 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 3Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 4Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 5Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 2Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 3Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 4
(Date:7/30/2014)... BEDFORD, Mass., July 30, 2014  Hologic, Inc. (NASDAQ: ... the third fiscal quarter ended June 28, 2014. ... , Revenues increased 1.0% to $632.6 million, reflecting operational ... 0.5%, compared to the same period in the prior ... four business segments. , Breast Health revenues grew 3.5%. ...
(Date:7/30/2014)... -- CryoLife, Inc. (NYSE: CRY), a leading medical device ... surgery, announced today that its Board of Directors has ... 2014 of $0.03 per share of common stock outstanding.  ... be paid on September 19, 2014 to all common ... ex-dividend date for the quarterly dividend is September 10, ...
(Date:7/30/2014)... , July 30, 2014  Unilife Corporation ("Unilife" ... a developer and supplier of injectable drug delivery ... manufacturing capacity, R&D, and facilities in response to ... its products and services. During the fourth quarter ... $16 million in capital expenditures and R&D above ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated ... of non-constipating irritable bowel syndrome (IBS). Top-line results ... times daily produced a statistically significant improvement in global ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer of ... first fiscal quarter ended September 30, 2009, compared with $2,001,896 ... 2.2%. , The first quarter of fiscal 2010 produced operating ... for the first quarter of fiscal 2009. The net loss ...
Cached Medicine Technology:Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 5Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3
Complete cytology platform....
... is the first in portability and performance. CTU ... need a flexible, portable system with the state-of-the-art features ... easily to an "E" size tank and has an ... where it is needed.,The CTU Travel Case allows you ...
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
... Total GHb Program separates ... hemoglobin regardless of phenotype ... Schiff Base. Patient results ... DCCT reference to ensure ...
Medicine Products: